Marksans Pharma Ltd. announced robust financial results for the first quarter of FY27 (Q1FY27). The company reported a 35.6% year-over-year increase in revenue, reaching ₹841 crore. EBITDA saw a substantial jump of 112.8% to ₹213 crore, and Profit After Tax (PAT) grew by an impressive 173.9% to ₹159 crore. These strong figures reflect the company’s expanding global presence and strategic growth initiatives.
Marksans Pharma Reports Strong Q1 FY27 Performance
Marksans Pharma Ltd. has released its financial results for the first quarter of the fiscal year 2027 (Q1FY27), ending June 30, 2026. The company demonstrated significant year-over-year growth across key financial metrics, underscoring its solid operational performance and strategic market positioning.
Financial Highlights: Q1 FY27 vs. Q1 FY26
The company’s Operating Revenue for Q1FY27 stood at ₹840.8 crore, marking a substantial increase of 35.6% compared to ₹620.0 crore in Q1FY26. This growth was driven primarily by strong performance in the UK & Europe, contributing ₹356 crore, and sustained momentum in other key geographies.
Gross Profit rose by 38.9% to ₹497.3 crore from ₹358.2 crore in the prior year quarter. Consequently, the Gross Margin improved by 138 basis points to 59.1%.
EBITDA experienced remarkable growth of 112.8%, reaching ₹213.0 crore in Q1FY27, up from ₹100.1 crore in Q1FY26. The EBITDA Margin expanded significantly by 919 basis points to 25.3%.
Profit After Tax (PAT) surged by 173.9% to ₹159.4 crore in Q1FY27, compared to ₹58.2 crore in Q1FY26. The Net Profit Margin improved substantially to 18.4%.
Geographical Performance Insights
The revenue breakdown by geography highlights strong contributions from US & North America (₹377 crore, +15.1% YoY) and UK & Europe (₹356 crore, +74.7% YoY). Australia & New Zealand also showed robust growth with ₹88 crore (+53.7% YoY), while the Rest of World segment contributed ₹20 crore (-36.8% YoY).
Strategic Progress and Balance Sheet Strength
The company reported strategic progress, including the establishment of its Europe front-end with acquisitions like QliniQ B.V. and ABCnow GmbH. Marksans Pharma maintained a strong balance sheet with a cash balance of ₹1,058 crore as of June 30, 2026, and a net cash position of ₹1,031 crore, indicating strong cash generation and disciplined capital allocation.
Source: BSE
